Sunday, 22 January 2023

 INTIMATION FOR BODHIKA SEMINAR - 25/01/2023

DEPARTMENT OF  KAUMARABHRITYA

GOVT. AYURVEDA COLLEGE, THIRUVANANTHAPURAM


NAME  OF  FIRST PRESENTEEDr RAKHI KRISHNAN

DISSERTATION TITLE: EFFECT OF KALYANAKA AVALEHA CHOORNA ALONG WITH GHRITA (GHEE)IN LANGUAGE IMPAIRMENT OF CHILDREN WITH AUTISM AGED 3-6YEARS

NAME OF GUIDE:  Dr SAREENA K M.D(Ay)                              

DATE:28/01/2023

TIME: 2:00-4:00 PM

VENUE: OFFLINE AT COLLEGE AUDITORIUM


ABSTRACT

The essential features of Autism Spectrum Disorders(ASD) are persistent impairment in reciprocal social communication and interaction and restricted, patterns of behaviour or interests. Failure to meet the language development milestones is one of the earliest red flags of Autism. There will be language delay; regression or loss of use of speech. Receptive language often lags behind expressive language in ASD.  At one end, there are children with Autism whose vocabulary, grammatical knowledge, and articulation skills are within the normal range of functioning, while at the other end, a significant proportion of the population remains essentially nonverbal. Marked changes can be observed if ayurvedic formulations that can stimulate the language areas of the brain can be given to such children.

 

A clinical study is designed to evaluate the effect of Kalyanaka Avaleha Choorna in a dose of 3 gm, twice daily, after food, with ghrita in language impairment of children with autism aged 3-6 years for a period of 60 days. The formulation Kalyanaka Avaleha Choorna is explained in the Bhaishajya Ratnavali- Swarabheda Chikitsa and Vatavyadhi Chikitsa and also Chakradatha –Vatavyadhi Chikitsa.

The study is conducted as an Interventional assignment with Pre and Post-test. Children of both sex of the age group 3-6 years having qualitative impairment in the areas of language development or communication skills, social interactions, and reciprocity satisfying the DSM – 5 attending the OPD of Kaumarabhritya will be selected for the study. Assessment for Autism is done using the tool CARS (Childhood Autism Rating Scale) & language age evaluation is done using the tool Receptive-Expressive Emergent Language Scale (REELS) by a Speech and language pathologist. Both assessments will be taken before and after the study. A Further assessment will be done after 1 month of follow-up period. Data will be analysed using paired t test.




NAME  OF  SECOND PRESENTEEDr REENU MATHEW

      



DISSERTATION TITLE: EFFECT OF KALYANAKA CHURNA IN THE MANAGEMENT OF INTRACTABLE EPILEPSY IN CHILDREN ON ANTI EPILEPTIC DRUGS BETWEEN THE AGE GROUP 3-12 YEARS


NAME OF GUIDE: Dr ANILKUMAR M.V M.D(Ay)    
NAME OF CO-GUIDE:Dr SHAHANAZ AHAMED M         

DATE:28/01/2023

TIME: 2:00-4:00 PM

VENUE: OFFLINE AT COLLEGE AUDITORIUM


ABSTRACT

Epilepsy is a disorder of brain characterized by an enduring predisposition to generate epileptic seizures. It includes recurrent, episodic, paroxysmal, involuntary clinical events associated with abnormal electrical activity from the neurons. Intractable epilepsy is defined as occurrence of one or more seizures per month, despite a trial of the correct anti- epileptic drugs (AEDs) in adequate doses for 2 years. Epilepsy is being managed by modern medicine with the help of anti-epileptic drugs but some remain intractable or refractory for management. Ayurvedic intervention along with AED is expected to give promising result.

                    A clinical study is designed to evaluate the effect of Kalyanaka Churna in intractable epilepsy in children between 3-12 years. Kalyanaka Churna is described in Bhavaprakasa, madhyama khanda, Apasmara adhikara.The study will be conducted as an interventional assignment, pre and posttest. The study will be carried out in OutPatient Department of Kaumarabhritya, Govt. Ayurveda College Hospital for Women and Children, Thiruvananthapuram. Children of both sex of age 3-12 years, of population 12 who are affected with epilepsy and not effectively managed by AEDs will be included in the study, screened and assessed using Hague Seizure Severity Scale, Electroencephalogram and Quality of life in childhood epilepsy. Then the trial drug Kalyanaka Churna will be given in a dose of 1.5gm for the age group 3-6 years and 2.5gm for the age group 7-12 years, twice daily after food with warm water as anupana. The trial drug will be given for a period of 90 days. The participants will be allowed to continue the AEDs they are taking in the same dose throughout the study period. The participants will be assessed before and after treatment using Hague Seizure Severity Scale, Electroencephalogram and Quality of life in childhood epilepsy. Data will be collected and statistically analyzed using Wilcoxon signed rank test and Paired-t test.




No comments: